State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
J Med Chem. 2020 Oct 8;63(19):11149-11168. doi: 10.1021/acs.jmedchem.0c01116. Epub 2020 Sep 18.
The Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)-ARE (antioxidant response element) pathway is the major defending mechanism against oxidative stresses, and directly disrupting the Keap1-Nrf2 protein-protein interaction (PPI) has been an attractive strategy to target oxidative stress-related diseases, including cardiovascular diseases. Here, we describe the design, synthesis, and structure-activity relationships (SARs) of indoline-based compounds as potent Keap1-Nrf2 PPI inhibitors. Comprehensive SAR analysis and thermodynamics-guided optimization identified as the most potent inhibitor in this series, with an IC of 22 nM in a competitive fluorescence polarization assay. Further evaluation indicated the proper drug-like properties of . Compound dose-dependently upregulated genes and protein level of Nrf2 as well as its downstream markers and showed protective effects against lipopolysaccharide-induced injury in both H9c2 cardiac cells and mouse models. Collectively, we reported here a novel indoline-based Keap1-Nrf2 PPI inhibitor as a potential cardioprotective agent.
Keap1(Kelch-like ECH-associated protein 1)-Nrf2(核因子红细胞 2 相关因子 2)-ARE(抗氧化反应元件)通路是对抗氧化应激的主要防御机制,直接破坏 Keap1-Nrf2 蛋白-蛋白相互作用(PPI)一直是针对与氧化应激相关的疾病(包括心血管疾病)的一种有吸引力的策略。在这里,我们描述了基于吲哚啉的化合物作为有效的 Keap1-Nrf2 PPI 抑制剂的设计、合成和构效关系(SAR)。全面的 SAR 分析和热力学指导的优化确定 是该系列中最有效的抑制剂,在竞争性荧光偏振测定中 IC 为 22 nM。进一步的评估表明 具有适当的类药性。化合物 剂量依赖性地上调 Nrf2 及其下游标志物的基因和蛋白水平,并显示出对脂多糖诱导的 H9c2 心脏细胞和小鼠模型损伤的保护作用。总之,我们在这里报道了一种新型的基于吲哚啉的 Keap1-Nrf2 PPI 抑制剂,作为一种潜在的心脏保护剂。